This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Medicines Company's Inclisiran Studies to Continue Unmodified
by Zacks Equity Research
The Medicines Company (MDCO) announces that Independent Data Monitoring Committee has recommended that the ongoing phase III studies of its candidate, inclisiran, will continue without modification.
Jazz Pharmaceuticals' sNDA for Xyrem Gets Priority Review
by Zacks Equity Research
Jazz Pharmaceuticals' (JAZZ) label expansion application for Xyrem in pediatric patients gets priority review from the FDA.
Infinity and Arcus Ink Deal for Two Triple Combo Studies
by Zacks Equity Research
: Infinity Pharmaceuticals, Inc. (INFI) and Arcus Biosciences, Inc. (RCUS) sign a deal to evaluate two triple combination therapies in selected tumor types.
Puma Biotechnology's Shares Rise on Positive CHMP Trend Vote
by Zacks Equity Research
Puma Biotechnology's (PBYI) marketing application seeking approval for neratinib in breast cancer gets positive CHMP trend vote, following a negative opinion in February.
Lilly's Diabetes Drugs Meet Endpoints in Phase III Studies
by Zacks Equity Research
Lilly's (LLY) Jardiance and Humulin, being evaluated in separate phase III studies, meet primary endpoint of reduction in blood sugar level.
Roche's (RHHBY) Flu Candidate Gets Priority Review by the FDA
by Zacks Equity Research
Roche's (RHHBY) member Genentech announces that the FDA has accepted a new drug application (NDA) and granted priority review to its baloxavir marboxil to treat patients suffering from influenza A and influenza B.
Pfizer's Breast Cancer Drug Misses Overall Survival in Study
by Zacks Equity Research
Pfizer (PFE) announces that in the phase III PALOMA-3 study, the combination of Ibrance and Faslodex failed to improve overall survival in women with breast cancer compared with Faslodex and placebo.
Merrimack Crashes as Phase II Pancreatic Cancer Study Fails
by Zacks Equity Research
Merrimack (MACK) plunges, following the announcement of failure of the CARRIE phase II study on pipeline candidate, MM-141, for the treatment of metastatic pancreatic cancer.
Novo Nordisk (NVO) Announces Results in Diabetes Studies
by Zacks Equity Research
Novo Nordisk (NVO) announces results from a number of studies being evaluated to treat diabetes.
Anika Reports Top Line Data from CINGAL Study, Shares Slump
by Zacks Equity Research
Anika Therapeutics' (ANIK) shares declined 37%, after the company reported disappointing data from its phase III Cingal 16-02 study in treating patients with osteoarthritis (OA) in the knee.
Novo Nordisk in Deal with Kallyope for Obesity, Diabetes Drugs
by Zacks Equity Research
Novo Nordisk (NVO) enters into a research collaboration and option agreement with Kallyope, Inc. to develop novel therapies for diabetes and obesity.
Alexion (ALXN) Submits Application for ALXN1210 with FDA
by Zacks Equity Research
Alexion Pharmaceuticals, Inc. (ALXN) submits a Biologics License Application (BLA) to the FDA for approval of ALXN1210 to treat patients with paroxysmal nocturnal hemoglobinuria (PNH).
Roche to Buy Rest of Foundation Medicine for $2.4 billion
by Zacks Equity Research
Roche inks a deal with Foundation Medicine to acquire the remaining shares of Foundation Medicine, not already owned by it for a total consideration of $2.4 billion.
4 Undervalued MedTech Stocks to Consider Amid Volatility
by Zacks Equity Research
Amid turbulences of the U.S. market, some value stocks of MedTech industry appear to be lucrative investment options.
Flex Pharma Down on Workforce Reduction, Ends Phase II Study
by Zacks Equity Research
Flex Pharma (FLKS) announced that the company is ending the phase II studies for its pipeline candidate FLX-787 in two indications. The company also plans to lower its workforce by about 60%.
Sarepta Inks Manufacturing Deal for Gene Therapy Program
by Zacks Equity Research
Sarepta (SRPT) strikes manufacturing partnership with Brammer Bio to support its gene therapy development.
Here's Why Sarepta is Up More Than 60% So Far This Year
by Zacks Equity Research
Sarepta's (SRPT) key product, Exondys 51, continue to perform well and lead pipeline candidate, golodirsen, progresses well in 2018.
BioMarin's Palynziq Gets FDA Approval for Phenylketonuria
by Zacks Equity Research
BioMarin's (BMRN) enzyme therapy, Palynziq (pegvaliase) gets approval for the treatment of phenylketonuria in adult patients.
INSYS Gets Negative FDA Recommendation for Pain Candidate
by Zacks Equity Research
INSYS Therapeutics' (INSY) NDA for buprenorphine sublingual spray fails to get recommendation for approval for treating moderate-to-severe acute pain after bunionectomy from FDA advisory committee.
Ligand Pharmaceuticals (LGND) Hits a 52-Week High, Can the Run Continue?
by Zacks Equity Research
Ligand Pharmaceuticals Incorporated is at a 52-week high, but can investors hope for more gains in the future? We take a look at the fundamentals for LGND for clues.
Should Value Investors Pick ANI Pharmaceuticals (ANIP) Stock?
by Zacks Equity Research
Let's put ANI Pharmaceuticals (ANIP) stock into this equation and find out if it is a good choice for value-oriented investors right now.
Pfizer Hikes Dividend, Announces $10B Share Buyback Plan
by Zacks Equity Research
Pfizer (PFE) raises quarterly dividend for 2018 while also authorizing a new $10 billion share repurchase program.
Spectrum Doubles in 3 Months: What's Driving the Rally?
by Zacks Equity Research
Spectrum (SPPI) focuses on developing pipeline candidates. The stock doubled in the last three months mainly on encouraging data from poziotinib study.
ANI Pharmaceuticals (ANIP) Catches Eye: Stock Jumps 17.7%
by Zacks Equity Research
ANI Pharmaceuticals (ANIP) shares rose nearly 18% in the last trading session, amid huge volumes.
Moving Average Crossover Alert: ANI Pharmaceuticals (ANIP)
by Zacks Equity Research
ANI Pharmaceuticals, Inc. (ANIP) could be a stock to avoid from a technical perspective, as the firm is seeing unfavorable trends on the moving average crossover front